Form 8-K - Current report:
SEC Accession No. 0001193125-24-242808
Filing Date
2024-10-24
Accepted
2024-10-24 16:06:00
Documents
16
Period of Report
2024-10-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d881076d8k.htm   iXBRL 8-K 41636
2 EX-2.1 d881076dex21.htm EX-2.1 652659
3 EX-99.1 d881076dex991.htm EX-99.1 23537
7 GRAPHIC g881076g1024091034109.jpg GRAPHIC 2206
  Complete submission text file 0001193125-24-242808.txt   1007113

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA lyel-20241024.xsd EX-101.SCH 2845
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE lyel-20241024_lab.xml EX-101.LAB 17236
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lyel-20241024_pre.xml EX-101.PRE 10809
18 EXTRACTED XBRL INSTANCE DOCUMENT d881076d8k_htm.xml XML 3508
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 241392663
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)